Following a full submission
AWMSG advice |
|||
| Status: Recommended | |||
Midazolam (BUCCOLAM®) is recommended as an option for use within NHS Wales for the treatment of prolonged, acute, convulsive seizures in infants, toddlers, children and adolescents (from 3 months to < 18 years). For infants between 3–6 months of age treatment should be in a hospital setting where monitoring is possible and resuscitation equipment is available. Midazolam (BUCCOLAM®) should be prescribed by brand name to reduce the risk of medication errors. |
|||
|
|||
Medicine details |
|||
| Medicine name | midazolam (Buccolam®) | ||
| Formulation | oromucosal solution | ||
| Reference number | 1046 | ||
| Indication | Treatment of prolonged, acute, convulsive seizures in infants, toddlers, children and adolescents (from 3 months to < 18 years). Buccolam must only be used by parents/carers where the patient has been diagnosed to have epilepsy. For infants between 3-6 months of age treatment should be in a hospital setting where monitoring is possible and resuscitation equipment is available |
||
| Company | Shire Pharmaceuticals Ltd | ||
| BNF chapter | Central nervous system | ||
| Submission type | Full | ||
| Status | Recommended | ||
| Advice number | 0912 | ||
| NMG meeting date | 28/03/2012 | ||
| AWMSG meeting date | 09/05/2012 | ||
| Ratification by Welsh Government | 19/06/2012 | ||
| Date of issue | 19/06/2012 | ||
| Date of last review | 30/08/2016 | ||